Millions of people with attention deficit hyperactivity disorder take medication to manage their symptoms, yet a persistent worry has shadowed these treatments for years: could the drugs themselves push vulnerable patients toward self-harm? A new international study led by Aston University offers a striking answer. The risk of self-harm among people with ADHD, the researchers found, is highest before treatment begins, not after it starts, a pattern that held consistently across five different healthcare systems and does not support the idea that ADHD medications are the main driver of self-harm.
The research, led by Dr Adrienne Chan, a pharmacy lecturer, and Regius Professor Ian Wong of Aston Pharmacy School, was designed to address fears that taking ADHD medication raises the risk of self-harm. Those fears were fuelled by conflicting evidence from previous studies of ADHD medication, and the concerns matter enormously in practice, because they can influence whether people start or continue with treatment. Millions of adults and children worldwide have ADHD, and hesitation about medication safety can leave people without care that might otherwise help them. More recent studies had been more reassuring, but the question demanded a larger, more rigorous answer.
To get there, the multinational collaboration brought together the Aston University researchers and partner groups from UCL in the UK, the University of Hong Kong, the University of Auckland in New Zealand, Sungkyunkwan University in South Korea, and National Cheng Kung University in Taiwan. Additional collaborators came from Seoul National University in South Korea, the University of Melbourne in Australia, Rutgers University in the US, the University of Waterloo in Canada, the Chinese University of Hong Kong and Macau University of Science and Technology.
In one of the largest multinational studies of ADHD medication safety conducted to date, the research team analysed data from more than 460,000 people drawn from the healthcare systems of Hong Kong, New Zealand, South Korea, Taiwan and the UK. Every individual included had begun a course of ADHD medication and had a record of self-harm between 2001 and 2020. The study was published in BMJ Mental Health under the title ‘ADHD medication use and risk of self-harm: a multinational self-controlled case series study’, with the article publication date listed as 12 September 2026.
The analytical design deserves close attention, because it is what gives the findings their strength. The researchers used a self-controlled case series approach, a method in which each person serves as their own control. Rather than comparing medicated patients with unmedicated patients, a comparison vulnerable to confounding by differences in underlying health, the team compared periods of time within the same individuals.
Specifically, the researchers compared three periods of ADHD medication exposure with periods of non-exposure: the 90 days before treatment began, the first 90 days of treatment use, and the subsequent treatment period. By dividing each patient’s timeline in this way, the study could pinpoint when in the course of care the risk of self-harm was actually greatest, and whether that timing pointed toward the medication or away from it.
The answer was unambiguous. The highest risk of self-harm occurred during the 90 days immediately before starting treatment in all five healthcare systems. After treatment began, the risk was lower, although still elevated, compared with the pre-treatment window. The consistency of this pattern across five very different healthcare systems, spanning Asia, Europe and Australasia, is one of the most important features of the study. These consistent findings, the researchers report, do not support ADHD medications as the main driver of self-harm.
Dr Chan framed the implications in terms of opportunity rather than reassurance alone. ‘People often worry that ADHD medication itself increases the risk of self-harm,’ she said. ‘What our findings suggest is that many people are already at their highest risk before treatment even begins. This highlights an important opportunity for earlier intervention. Recognising that vulnerable period could help us provide support earlier, when it may make the greatest difference.’ In other words, the period when patients and families are most likely to be anxious about starting medication is precisely the period when patients are most at risk, and the study suggests that clinical attention should be concentrated there.
The researchers say the findings highlight the importance of closely monitoring people with ADHD, particularly those whose symptoms are worsening before they start treatment, so that support can be provided before self-harm occurs. That framing shifts the clinical conversation from a fear of the treatment to a focus on the untreated interval. It also aligns with the study’s central methodological insight: because the comparison is within individuals over time, the observed pre-treatment peak cannot be easily dismissed as an artefact of who ends up taking medication.
Beyond the immediate findings, the study has established an international research platform that can answer other important questions about medication safety. Future work will examine a wider range of health outcomes, including what happens when people stop or restart treatment, and whether ethnicity and socioeconomic disadvantage contribute to inequalities in ADHD care across different healthcare systems. Those questions matter because the current study covers people who began medication and had a record of self-harm between 2001 and 2020; it does not yet address the full range of outcomes that may follow discontinuation, restarting, or gaps in access to care.
Professor Wong emphasised the collaborative and data-governance dimensions of the work. ‘At Aston, we are committed to using big data not simply to answer scientific questions, but to generate evidence that helps clinicians, informs policy, and ultimately benefits patients,’ he said. ‘This study reflects that vision by bringing together expertise from five healthcare systems using a common scientific approach while keeping patient-level data securely within each country.
The study’s scope and limitations are worth stating plainly. It is an observational data analysis, not a randomised trial, so it can characterise the timing of risk rather than prove causal mechanisms. It included people who had begun a course of ADHD medication and had a record of self-harm, and it examined three defined exposure windows against periods of non-exposure. The findings speak to the relative timing of self-harm around the start of treatment; they do not, by themselves, establish why risk is elevated before treatment begins, although the researchers’ interpretation, that worsening symptoms in the period before care may place patients at their most vulnerable, is consistent with the pattern observed and with the call for earlier monitoring and support.
What the study does establish is substantial. In more than 460,000 people across five healthcare systems, using a design in which each patient served as their own control, the risk of self-harm peaked in the 90 days before ADHD medication was started and was lower after treatment began, in every system studied. For a question that has generated conflicting evidence and real-world hesitation about treatment, that is a meaningful contribution. The message for clinicians, patients and families is not that medication is a cure for risk, but that the feared direction of the effect, from drug to self-harm, is not what the data show. Instead, the most dangerous window appears to be the one that opens before treatment starts, when symptoms may be escalating and support may not yet have arrived. Recognising that window, the researchers argue, is where earlier intervention could make the greatest difference.
Subject of Research: The risk of self-harm among people with ADHD in relation to the timing of ADHD medication treatment across five healthcare systems.
Article Title: Aston University-led international study finds ADHD medication unlikely to raise risk of self-harm
Article References: Aston University-led international study finds ADHD medication unlikely to raise risk of self-harm. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: ADHD, ADHD medication, self-harm, mental health, pharmacoepidemiology, self-controlled case series, Aston University, BMJ Mental Health, medication safety, international collaboration, Hong Kong, United Kingdom
News Source: Ophelia Keating. (October 29, 2026). ADHD medication unlikely to raise self-harm risk, five-country study finds. Scienmag.
